Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism CK1ε inhibitors(casein kinase 1 epsilon inhibitors), PI3Kδ inhibitors(Phosphatidylinositol 3 kinase delta inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Peripheral T-Cell Lymphoma | Phase 3 | CN | 28 Jun 2024 | |
Non-Hodgkin's lymphoma refractory | Phase 1 | CN | 29 Dec 2021 | |
Recurrent Non-Hodgkin Lymphoma | Phase 1 | CN | 29 Dec 2021 | |
B-cell lymphoma recurrent | IND Approval | CN | 15 Dec 2023 | |
B-cell lymphoma refractory | IND Approval | CN | 15 Dec 2023 |
Phase 1 | 50 | (olkyajzung) = neutropenia, leukopenia, elevated alanine aminotransferase, elevated aspartate aminotransferase, thrombocytopenia, pneumonia, anemia, rash, elevated serum creatinine, sinus bradycardia, hyperuricemia, abnormal liver function, hypertriglyceridemia, diarrhea, and dermatitis medicamentosa lmzhcxptmp (lotfctbunn ) View more | Positive | 08 Dec 2024 | |||
Phase 1 | 24 | zyilewukzo(vmjcmsljln) = TRAEs occurring in ≥10% of patients were neutropenia, leukopenia, elevated alanine aminotransferase, elevated aspartate aminotransferase, elevated serum creatinine, thrombocytopenia, elevated blood bilirubin, rash, hypercholesteremia, pneumonia, upper respiratory infection, hyperlipidemia, hypertriglyceridemia, hyperuricemia, anemia, elevated blood lactate dehydrogenase and elevated gamma glutamyl transpeptidase oeqxpkxkds (gnjbdmnony ) View more | Positive | 08 Dec 2024 | |||
Phase 1 | 38 | (sutoctmddb) = cdgorgjbwc slkjaaaceq (wyhopbfmvo ) View more | - | 11 Dec 2023 |